Mi Youn Park
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Mi Youn Park has a total of 65 co-authors. Here are the top co-authors by number of shared publications:
- Jiyoung Ahn
Department of Dermatology National Medical Center Seoul Korea
16 shared publications - Hye Jung Jung
Department of Dermatology National Medical Center Seoul Korea
14 shared publications - Narang Hong
Department of Dermatology, National Medical Center, Seoul, Korea
11 shared publications - Hyung Don Kook
Department of Dermatology, National Medical Center, Seoul, Korea
9 shared publications - Dong Heon Lee
Department of Dermatology, National Medical Center, Seoul, Korea
8 shared publications - So Yun Park
Department of Dermatology, National Medical Center, Seoul, Korea
7 shared publications
Latest Publications
- Open Access
- 1 January 2026
- Published by XMLink in Allergy, Asthma & Immunology Research
- Vol. 18 (3) , 440-452
Real-World Efficacy and Safety of Upadacitinib in Korean Patients With Atopic Dermatitis
Park SY, et al. Allergy Asthma Immunol Res. 2026 May;18(3):440-452. https://doi.org/10.4168/aair.2026.18.3.440
- 1 January 2026
- Published by XMLink in Allergy, Asthma & Immunology Research
- Vol. 18 (3) , 440-452
Open AccessReal-World Efficacy and Safety of Upadacitinib in Korean Patients With Atopic Dermatitis
Park SY, et al. Allergy Asthma Immunol Res. 2026 May;18(3):440-452. https://doi.org/10.4168/aair.2026.18.3.440
- Open Access
- 1 January 2026
- Published by XMLink in Annals of Dermatology
- Vol. 38 (3) , 183-190
Baricitinib for Itch-Dominant Atopic Dermatitis: A 52-week Baricitinib Real-World Experience in Korea
Hong N, et al. Ann Dermatol. 2026 Jun;38(3):183-190. https://doi.org/10.5021/ad.25.162
- 1 January 2026
- Published by XMLink in Annals of Dermatology
- Vol. 38 (3) , 183-190
Open AccessBaricitinib for Itch-Dominant Atopic Dermatitis: A 52-week Baricitinib Real-World Experience in Korea
Hong N, et al. Ann Dermatol. 2026 Jun;38(3):183-190. https://doi.org/10.5021/ad.25.162
- Open Access
- 31 December 2025
- Published by The Korean Society for Psoriasis in Journal of the Korean Society for Psoriasis
- Vol. 22 (2) , 97-100
A case of morphea in a patient treated with guselkumab
So Yun Park, Min Jung Park, Ho Eun Gwag, Narang Hong, Jiyoung Ahn, Mi Youn Park, Hye Jung Jung. Journal of the Korean Society for Psoriasis 2025;22:97-100. https://doi.org/10.23203/JKSP.2025.22.2.97
- 31 December 2025
- Published by The Korean Society for Psoriasis in Journal of the Korean Society for Psoriasis
- Vol. 22 (2) , 97-100
Open AccessA case of morphea in a patient treated with guselkumab
So Yun Park, Min Jung Park, Ho Eun Gwag, Narang Hong, Jiyoung Ahn, Mi Youn Park, Hye Jung Jung. Journal of the Korean Society for Psoriasis 2025;22:97-100. https://doi.org/10.23203/JKSP.2025.22.2.97
- 30 April 2024
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 38 (10) , 1939-1946
Detecting T‐cell receptor clonality in patients with severe atopic dermatitis refractory to dupilumab
Background: Trials and real‐life studies demonstrated clinically meaningful improvements of disease activity in the majority of patients with moderate to severe atopic dermatitis (AD) treated with the anti‐IL‐4RA‐antibody dupilumab. However, misdiagnosis or confounding skin diseases in particular cutaneous T‐cell lymphoma (CTCL) may lead to inadequate response.Objective: To investigate the clinical and pathological features of patients with AD who showed insufficient response to dupilumab.Methods: We reviewed the medical records of 371 patients treated with dupilumab for severe AD. Insufficient response was defined as failure to achieve an improvement of the eczema area severity index (EASI) of at least 50% (EASI‐50) at Week 16 and of 75% (EASI‐75) at Week 52. Among 46 patients with insufficient response, 35 patients consented to a re‐evaluation including a full physical exam, biopsies and laboratory assessments including immunohistochemistry and T‐cell receptor gene rearrangement analysis to differentiate CTCL.Results: Of the 371 patients treated with dupilumab, 46 (12.3%) patients showed insufficient response to dupilumab. Of these, 35 underwent further evaluation, and 19 (54.2% of inadequate responders) were finally diagnosed with mycosis fungoides (MF). In these patients, transition to or addition of conventional MF treatment led to clinical improvements.Conclusions: Insufficient response to dupilumab treatment may help uncover early MF on an existing AD background.
- 30 April 2024
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 38 (10) , 1939-1946
Detecting T‐cell receptor clonality in patients with severe atopic dermatitis refractory to dupilumab
Background: Trials and real‐life studies demonstrated clinically meaningful improvements of disease activity in the majority of patients with moderate to severe atopic dermatitis (AD) treated with the anti‐IL‐4RA‐antibody dupilumab. However, misdiagnosis or confounding skin diseases in particular cutaneous T‐cell lymphoma (CTCL) may lead to inadequate response.Objective: To investigate the clinical and pathological features of patients with AD who showed insufficient response to dupilumab.Methods: We reviewed the medical records of 371 patients treated with dupilumab for severe AD. Insufficient response was defined as failure to achieve an improvement of the eczema area severity index (EASI) of at least 50% (EASI‐50) at Week 16 and of 75% (EASI‐75) at Week 52. Among 46 patients with insufficient response, 35 patients consented to a re‐evaluation including a full physical exam, biopsies and laboratory assessments including immunohistochemistry and T‐cell receptor gene rearrangement analysis to differentiate CTCL.Results: Of the 371 patients treated with dupilumab, 46 (12.3%) patients showed insufficient response to dupilumab. Of these, 35 underwent further evaluation, and 19 (54.2% of inadequate responders) were finally diagnosed with mycosis fungoides (MF). In these patients, transition to or addition of conventional MF treatment led to clinical improvements.Conclusions: Insufficient response to dupilumab treatment may help uncover early MF on an existing AD background.
- Open Access
- 1 January 2024
- Published by XMLink in Annals of Dermatology
- Vol. 36 (1) , 35-43
Consensus Report on Truncal Acne: The Korean Acne and Rosacea Society Experts Panel
Ko JY, et al. Ann Dermatol. 2024 Feb;36(1):35-43. https://doi.org/10.5021/ad.23.057
- 1 January 2024
- Published by XMLink in Annals of Dermatology
- Vol. 36 (1) , 35-43
Open AccessConsensus Report on Truncal Acne: The Korean Acne and Rosacea Society Experts Panel
Ko JY, et al. Ann Dermatol. 2024 Feb;36(1):35-43. https://doi.org/10.5021/ad.23.057
- Open Access
- 1 January 2023
- Published by XMLink in Annals of Dermatology
- Vol. 35 (Suppl 2) , S310-S313
Very Early Patch Stage of AIDS-related Kaposi Sarcoma: A Case Report
Lee DH, et al. Ann Dermatol. 2023 Nov;35:e164. https://doi.org/10.5021/ad.22.023
- 1 January 2023
- Published by XMLink in Annals of Dermatology
- Vol. 35 (Suppl 2) , S310-S313
Open AccessVery Early Patch Stage of AIDS-related Kaposi Sarcoma: A Case Report
Lee DH, et al. Ann Dermatol. 2023 Nov;35:e164. https://doi.org/10.5021/ad.22.023
- Open Access
- 1 January 2023
- Published by XMLink in Annals of Dermatology
- Vol. 35 (Suppl 2) , S208-S210
Tuberculous Lymphadenitis in a Patient Treated with Dupilumab: A Case Report
Lee DH, et al. Ann Dermatol. 2023 Oct;35:e118. https://doi.org/10.5021/ad.21.241
- 1 January 2023
- Published by XMLink in Annals of Dermatology
- Vol. 35 (Suppl 2) , S208-S210
Open AccessTuberculous Lymphadenitis in a Patient Treated with Dupilumab: A Case Report
Lee DH, et al. Ann Dermatol. 2023 Oct;35:e118. https://doi.org/10.5021/ad.21.241
- 15 September 2022
- Published by Wiley in Dermatologic Therapy
- Vol. 35 (11) , e15802
Successful treatment of atopic dermatitis refractory to dupilumab with baricitinib
- 15 September 2022
- Published by Wiley in Dermatologic Therapy
- Vol. 35 (11) , e15802
Successful treatment of atopic dermatitis refractory to dupilumab with baricitinib
- 2 August 2022
- Published by Wiley in Dermatologic Therapy
- Vol. 35 (9) , e15728
Baricitinib rapidly relieves eczema associated pruritus in elderly patients
- 2 August 2022
- Published by Wiley in Dermatologic Therapy
- Vol. 35 (9) , e15728
Baricitinib rapidly relieves eczema associated pruritus in elderly patients
- 12 July 2022
- Published by Hindawi Limited in Dermatologic Therapy
- Vol. 35 (7)
Cover Image, Volume 35, Issue 7
- 12 July 2022
- Published by Hindawi Limited in Dermatologic Therapy
- Vol. 35 (7)
Cover Image, Volume 35, Issue 7